Pharvaris NV Dossier
Qualitative Analysis
Business overview
Pharvaris N.V. (Nasdaq: PHVS) is a late-stage biopharmaceutical company incorporated in 2015 and headquartered in Zug, Switzerland. The company is dedicated to developing and commercializing innovative, oral small-molecule bradykinin B2 receptor antagonists to address significant unmet needs in bradykinin-mediated diseases, primarily hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Pharvaris's core therapeutic candidate is deucrictibant, which is being developed in two distinct oral formulations: an immediate-release (IR) capsule designed for rapid onset of action in on-demand treatment of acute HAE attacks, and an extended-release (XR) tablet designed for sustained absorption to prevent HAE attacks (prophylaxis). By offering oral alternatives with injectable-like efficacy and placebo-like tolerability, Pharvaris aims to establish a new standard of care that significantly improves patient convenience and quality of life.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Establishing commercial infrastructure and expanding the sales and marketing team in the U.S. in preparation for the potential commercial launch of deucrictibant immediate-release (IR) capsule for the on-demand treatment of HAE attacks.
Expected impact: Enables rapid market entry and commercial execution upon potential FDA approval of deucrictibant IR.
Advancing clinical development of deucrictibant into acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) through the ongoing global, pivotal Phase 3 CREAATE study.
Expected impact: Expands the therapeutic indications of deucrictibant beyond hereditary angioedema into acquired angioedema, broadening the addressable patient population.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations